Halozyme Therap

HALO

----

Current ValuationThe current P/E ratio is 30.11, above the reasonable range, cheaper than 1.66% of the time in the past 3 years, and the industry ranks 47/602, the industry Median -2.08.

30.11xP/E

Stock price$109.72Earnings per share$3.64

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
ARGXUSArgenx	33.93x	37.17%	$58.19B
BIIBUSBiogen	39.46x	30.25%	$32.93B
ALNYUSAlnylam Pharma	38.68x	186.16%	$29.97B
HALOUSHalozyme Therap	30.11x	181.51%	$12.45B
KRYSUSKrystal Biotech	40.06x	10.42%	$9.67B
VCYTUSVeracyte	31.35x	35.02%	$3.59B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.